CTLA4 and posterior cortical atrophy: Despite the efficacy of immune checkpoint inhibitors such as ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) in a variety of cancers including melanoma [53], lung [54], kidney [55] and breast [56], clinical trials for these drugs in Pca have found them relatively inert or even toxic.